Advertisement

Progress in the US With Biosimilars, but Opportunities Remain

Published on: 

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of AJMC®'s The Center for Biosimilars®, highlights recent progress, how the US market compares with Europe, and what remains to be seen.

You may need to log in to the website to access this podcast.

iTunes

Advertisement

Advertisement
Advertisement